Angiosarcoma Diagnosis and Treatment Strategies

Angiosarcoma is a rare and highly aggressive malignancy arising from the endothelial lining of blood or lymphatic vessels. It most commonly affects skin, breast, liver and deep soft tissues and is characterised by rapid progression and a high propensity for metastasis. Early diagnosis is complicated by its heterogeneous clinical presentation, which can range from subtle bruise-like lesions to rapidly enlarging masses. Diagnostic work-up integrates cross-sectional imaging—magnetic resonance imaging and computed tomography—to delineate tumour extent, followed by histopathological examination. Immunohistochemical markers such as CD31, CD34 and ERG confirm endothelial origin and distinguish angiosarcoma from other soft tissue neoplasms. Advances in molecular profiling have identified recurrent alterations in angiogenesis-related pathways, notably vascular endothelial growth factor receptor signalling, mitogen-activated protein kinase activation and MYC amplifications in secondary tumours. Standard treatment remains complete surgical excision with negative margins, often supplemented by adjuvant radiotherapy to reduce local recurrence. In advanced or metastatic settings, conventional chemotherapeutic agents, including taxanes and anthracyclines, yield modest and often short-lived responses. Emerging strategies focus on targeted therapies—such as tyrosine kinase inhibitors against VEGF receptors—and immunotherapies, particularly immune checkpoint inhibitors, which have shown activity in selected patient cohorts. The development of patient-derived preclinical models, including three-dimensional organoids, promises personalised drug screening and mechanistic insights. A coordinated, multidisciplinary approach is essential to improve outcomes for this challenging disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Angiosarcoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in angiosarcoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Angiosarcoma: A malignant tumour originating from the endothelial cells of blood or lymphatic vessels.

Organoid: A three-dimensional cell culture model derived from patient tissue that mimics the architecture and functionality of the original tumour.

Immune checkpoint inhibitor: A therapeutic antibody that blocks inhibitory pathways in T cells, thereby enhancing antitumour immune responses.

Neoantigen: A tumour-specific peptide generated by somatic mutation, capable of eliciting a targeted immune reaction.

Tyrosine kinase inhibitor: A small molecule that inhibits enzymatic activity of tyrosine kinases involved in signalling pathways essential for tumour proliferation and survival.

References

1. Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment. Journal of Hematology & Oncology (2024).
2. Genomic profiling of radiation-induced sarcomas reveals the immunological characteristics and its response to immune checkpoint blockade. Clinical Cancer Research (2023).
3. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget (2015).
4. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer (2017).
5. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). Journal for ImmunoTherapy of Cancer (2021).